Telix at AUA 2026

Join Telix at the American Urological Association’s 2026 Annual Meeting, taking place this week in Washington, DC.

#AUA2026 will feature presentations across Telix’s urologic oncology portfolio, including ⁸⁹Zr-girentuximab PET/CT (TLX250-Px) for kidney cancer and ⁶⁸Ga-PSMA-11 PET/CT for prostate cancer imaging (Phase 3 BiPASS trial).

The presentations highlight the increasing role of targeted imaging in supporting diagnosis, treatment planning and disease management across these disease areas with unmet need.

Join us at these presentations or visit us at Booth #1215 to chat to #TeamTelix.

Learn more about presence below.

TLX250-Px has not received a marketing authorization in any jurisdiction.

15-18 May 2026

Washington, DC, United States

Abstract presentations 

May 15
May 17
May 18
Ancillary Events
May 15
Gianpaolo Carpinito

University of North Carolina
at Chapel Hill
Defining use cases for [89Zr]-girentuximab PET/CT (TLX250-Px) in urologic oncology: Insights from an SUO member survey

Abstract #IP08-24

May 15 | 9:30 AM – 11:30 AM EDT

Philipose Mulugeta

University of Pennsylvania
Sub-5-minute denoised PET imaging of indeterminate renal masses using [89Zr]-girentuximab (TLX250-Px): A feasibility study

Abstract #IP08-25

May 15 | 9:30 AM – 11:30 AM EDT

May 17
Clint Bahler

Indiana University
Phase 3 study of 68Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer (BiPASS) NCT07052214

Hall B, The Square, Learning Lab

May 17 | 1:16 PM – 1:24 PM EDT

Jon Henderson

Arkansas Urology
Expanded access program for the noninvasive detection of CAIX-expressing ccRCC in patients with renal masses utilizing [89Zr]-girentuximab PET/CT (TLX250-Px)

Abstract #IP71-11

May 17 | 3:30 PM – 5:30 PM EDT

Genesis Dolgetta

Sarasota Memorial Health
Non-invasive detection of ccRCC in patients with renal masses utilizing [89Zr]-girentuximab PET/CT (TLX250-Px) for intervention versus surveillance decision making

Abstract #IP71-10

May 17 | 3:30 PM – 5:30 PM EDT

May 18
Burak Akgul

Indiana University
Recurrence patterns after deferred treatment in biochemically recurrent prostate cancer following a negative PSMA PET/CT

Abstract #IP79-14

May 18 | 9:30 AM – 11:30 AM EDT

Ancillary Events
AUA Extended Conversation
BiPASS: Redefining the Prostate Cancer Journey Through Earlier More Precise Diagnosis
Dr. Brian Mazzarella
Urologist
Austin Urology

Dr. Timothy McClure
A/Prof of Urology
Weill Cornell Medical College

Where: Learning Lab in AUA Square
When: Sun, May 17 | 3 PM – 3:30 PM EDT

The Unmet Need in ccRCC Imaging
&
How PSMA Imaging Guides Therapy in Radiation Oncology
Dr. Dan Joyce
Professor of Urology
Vanderbilt University Medical Center

Dr. Daniel Kim
Director of Radiation Oncology
Inova Cancer Institute

Where: Product Theater 1, Booth #2701
When: Sat, May 16 | 2:30 PM – 3:15 PM EDT

Breakfast Symposium:
BiPASS: Redefining The Prostate Cancer Journey Through Earlier More Precise Diagnosis
Dr. Brian Mazzarella
Urologist
Austin Urology

Where: Ballroom B
When: Thur, May 14 | 7:00 AM EDT

PSMA Molecular Imaging review of 18F-PSMA 
and [68Ga]-PSMA-11 Clinical Considerations in Radiation Oncology
&
BiPASS: Redefining The Prostate Cancer 
Journey Through Earlier More Precise Diagnosis
Dr. Munir Ghesani
Chief Medical Officer United Theranostics

Dr. Wayne Brisbane
Urologic Oncologist
UCLA Medical Center

Where: Product Theater 1, Booth #2701
When: Sun, May 17 | 11:30 AM – 12:15 PM EDT